Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) posted its earnings results on Tuesday. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15, Zacks reports. Bayer Aktiengesellschaft had a positive return on equity of 15.93% and a negative net margin of 8.51%. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY traded up $0.37 during trading hours on Tuesday, hitting $11.25. 408,939 shares of the company were exchanged, compared to its average volume of 1,249,461. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. Bayer Aktiengesellschaft has a 52-week low of $6.20 and a 52-week high of $14.85. The stock has a market capitalization of $44.21 billion, a price-to-earnings ratio of -10.14 and a beta of 0.62. The company’s 50 day moving average price is $11.31 and its 200-day moving average price is $10.91.

Wall Street Analysts Forecast Growth

BAYRY has been the subject of a number of recent analyst reports. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. DZ Bank raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.